In the analysis of BMI, three GLP‐1 RA‐based drugs showed significant efficacy in reducing BMI levels in nondiabetic adults with overweight or obesity, compared to placebo. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.